WASHINGTON — Elizabeth Jungman, a well-known public health expert and a Capitol Hill veteran, will lead the FDA’s regulatory policy office starting this summer, STAT has learned.
Jungman, who currently serves as head of public health programs at the Pew Charitable Trusts, will direct the FDA’s Office of Regulatory Policy, a post within the FDA’s Center for Drug Evaluation and Research with sweeping authority over FDA’s human drugs portfolio, two sources told STAT. The office is perhaps most known for its role in regulating drug compounding, although it has also led some of the FDA’s work on other hot-button issues like abuses of the agency’s safety systems and its regulation of homeopathic drugs.
Jungman’s hiring is the latest in a series of high-profile staff shake-ups among the agency’s compounding staff. Julie Dohm, who was the agency’s top compounding staffer until March, left the FDA to join the law firm Covington & Burling. (A replacement has not yet been announced for Dohm, who served as FDA’s senior science advisor for compounding.)